尿激酶型纤溶酶原激活物受体：恶性肿瘤的标志物？
Urokinase-type plasminogen activator receptor: a beacon of malignancy?
作者信息
Drapkin Ronny, Clauss Adam, Skates Steven
机构信息
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
出版信息
Clin Cancer Res. 2008 Sep 15;14(18):5643-5. doi: 10.1158/1078-0432.CCR-08-1557.
Abstract
Discriminating between benign and malignant disease is a pivotal diagnostic issue in the care of women with pelvic masses. Identification of serum biomakers that can rellably make the distinction would aid in the proper referral for patient care and may provide leads in the development of early detection strategies.
摘要
鉴别良性和恶性疾病是盆腔肿块女性患者护理中的一个关键诊断问题。识别能够可靠区分两者的血清生物标志物将有助于为患者护理进行适当的转诊，并可能为早期检测策略的开发提供线索。
相似文献
1
Urokinase-type plasminogen activator receptor: a beacon of malignancy?尿激酶型纤溶酶原激活物受体：恶性肿瘤的标志物？
Clin Cancer Res. 2008 Sep 15;14(18):5643-5. doi: 10.1158/1078-0432.CCR-08-1557.
2
Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer.血浆中尿激酶型纤溶酶原激活物受体的裂解形式具有诊断潜力，并可预测卵巢癌患者的术后生存率。
Clin Cancer Res. 2008 Sep 15;14(18):5785-93. doi: 10.1158/1078-0432.CCR-08-0096.
3
Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.通过测定卵巢癌FIGO II和III期患者血清中的尿激酶型纤溶酶原激活剂（uPA）和可溶性尿激酶型纤溶酶原激活剂受体（suPAR）来监测铂/紫杉醇化疗方案的化疗成功率。
Bosn J Basic Med Sci. 2007 May;7(2):111-6. doi: 10.17305/bjbms.2007.3063.
4
Detection of urokinase plasminogen activator receptor and c-erbB-2 in sera of patients with breast and ovarian carcinoma.乳腺癌和卵巢癌患者血清中尿激酶型纤溶酶原激活物受体及c-erbB-2的检测
Clin Biochem. 2003 Oct;36(7):537-43. doi: 10.1016/s0009-9120(03)00102-4.
5
Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients.可溶性尿激酶型纤溶酶原激活物受体的表达可能与前列腺癌患者的预后相关。
Oncol Rep. 2000 Jul-Aug;7(4):879-82. doi: 10.3892/or.7.4.879.
6
Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients.纤溶酶原激活物抑制剂-1是晚期上皮性卵巢癌患者生存的独立不良预后因素。
Int J Cancer. 1998 Oct 23;79(5):449-54. doi: 10.1002/(sici)1097-0215(19981023)79:5<449::aid-ijc1>3.0.co;2-0.
7
The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.卵巢癌患者血清中尿激酶型纤溶酶原激活物受体水平升高。
Cancer Res. 1998 May 1;58(9):1843-9.
8
High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer.尿激酶型纤溶酶原激活物受体在肿瘤组织中的高浓度与卵巢癌患者的良好预后相关。
Int J Cancer. 2003 Nov 20;107(4):658-65. doi: 10.1002/ijc.11420.
9
The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.血浆可溶性尿激酶型纤溶酶原激活物受体（suPAR）水平在Ⅲ期卵巢癌患者中的预后价值。
Anticancer Res. 2004 May-Jun;24(3b):1981-5.
10
Diagnostic and prognostic values of plasma levels of fibrinolytic markers in gastric cancer.胃癌中纤溶标志物血浆水平的诊断和预后价值
Thromb Res. 1998 Jul 1;91(1):23-7. doi: 10.1016/s0049-3848(98)00061-9.
引用本文的文献
1
Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival.在卵巢癌中，elafin 的过表达是由基因组增益和核因子 kappaB 途径的激活驱动的，并且与总体生存不良相关。
Neoplasia. 2010 Feb;12(2):161-72. doi: 10.1593/neo.91542.
本文引用的文献
1
Cancer statistics, 2008.2008年癌症统计数据。
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. doi: 10.3322/CA.2007.0010. Epub 2008 Feb 20.
2
The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.使用多种新型肿瘤生物标志物检测盆腔肿块患者的卵巢癌。
Gynecol Oncol. 2008 Feb;108(2):402-8. doi: 10.1016/j.ygyno.2007.10.017. Epub 2007 Dec 3.
3
The urokinase-system--role of cell proliferation and apoptosis.尿激酶系统——细胞增殖与凋亡的作用
Histol Histopathol. 2008 Feb;23(2):227-36. doi: 10.14670/HH-23.227.
4
How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design.如何提高分子标志物研究的可靠性和效率：阶段、指南及研究设计的作用
J Clin Epidemiol. 2007 Dec;60(12):1205-19. doi: 10.1016/j.jclinepi.2007.04.020. Epub 2007 Sep 24.
5
Influence of the gynecologic oncologist on the survival of ovarian cancer patients.妇科肿瘤学家对卵巢癌患者生存率的影响。
Obstet Gynecol. 2007 Jun;109(6):1342-50. doi: 10.1097/01.AOG.0000265207.27755.28.
6
The urokinase plasminogen activator receptor as a gene therapy target for cancer.尿激酶型纤溶酶原激活物受体作为癌症的基因治疗靶点。
Trends Biotechnol. 2007 Jan;25(1):33-9. doi: 10.1016/j.tibtech.2006.10.011. Epub 2006 Nov 7.
7
Aggressive surgical effort and improved survival in advanced-stage ovarian cancer.晚期卵巢癌积极的手术治疗与生存率的提高
Obstet Gynecol. 2006 Jan;107(1):77-85. doi: 10.1097/01.AOG.0000192407.04428.bb.
8
Cancer of the ovary.卵巢癌
N Engl J Med. 2004 Dec 9;351(24):2519-29. doi: 10.1056/NEJMra041842.
9
Progress and challenges in screening for early detection of ovarian cancer.卵巢癌早期检测筛查的进展与挑战
Mol Cell Proteomics. 2004 Apr;3(4):355-66. doi: 10.1074/mcp.R400006-MCP200. Epub 2004 Feb 5.
10
Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer.尿激酶型纤溶酶原激活物受体（uPAR）在癌症中表达的临床意义
Med Res Rev. 2004 Jan;24(1):13-39. doi: 10.1002/med.10054.
Zotero 插件